Article Listing - Revised EPHA position on clinical trials

NIGERIAN HEALTH SPENDING FOR 1992

6 April 1992

The federal government of Nigeria has announced a total figure for health care spending in 1992 of 192 million naira,...

AUSTRALIAN LAUNCH OF ROCHE'S AURORIX

6 April 1992

Hoffmann-La Roche's reversible inhibitor of monoamine oxidase type A, Aurorix (moclobemide) has now been launched in Australia. The novel antidepressant...

ARES-SERONO GAINS RIGHTS TO CUROSURF

6 April 1992

Swiss pharmaceutical group Ares-Serono has acquired exclusive marketing rights in most European territories for a natural pulmonary surfactant product, Curosurf,...

COMPANY NEWS FROM CHINA

6 April 1992

The Shanghai Medicines and Health Products Import and Export Corporation of China exported products worth $150 million in 1991, reports...

NEW PRES AT RHONE-POULENC RORER

6 April 1992

Rhone-Poulenc Rorer Inc has named Manfred Karobath as senior vice president, RPR, and president, RPR Research and Development. He was...

NEW PRES AT PROCORDIA

6 April 1992

Jan Ekberg has been named as president and chief executive at Procordia, in succession to Soren Gyll who has become...

PHARMA COs TOP R&D SPEND IN JAPAN

6 April 1992

Of 16 Japanese companies planning to spend over 10% of their sales on R&D in 1992, nine are pharmaceutical companies,...

US HOSPITAL FORMULARY GUIDE

6 April 1992

The American Society of Hospital Pharmacists has released guidelines on formulary system management for its members.

The ASHP notes that in...

GALLUP SURVEYS UK GPs ON HEPATITIS A

6 April 1992

With the recent introduction of its hepatitis A vaccine Havrix to the UK market, SmithKline Beecham has sponsored a Gallup...

GENENTECH REBUFFS ISIS-3 AND AWAITS GUSTO

6 April 1992

With the formal publication in The Lancet last week of the results of the ISIS-3 thrombolytic product trial, the major...